• Next Post
  • Previous Post

test

/ Uncategorized

Share the Post

About the Author

Related Posts

Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComa
Aadi Bioscience Receives Breakthrough Therapy Designation for ABI-009 in PEComa Indication
Read More
Anupam Dalal, MD
Evaluation of nab-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Read More
Bryan Ball
Phase I results from a phase 1/2 multi-center study of nab-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss
Aadi Bioscience Launches its Phase 2 Registration Trial for ABI-009PEComa

Comments

Comments are closed.

  • Next Post
  • Previous Post